For example, Friboulet et al. demonstrated that crizotinib-induced resistance mutations in ALK-fusion-positive non-small-cell lung cancer (NSCLC) can be overcome by treatment with ceritinib (Friboulet et al. 2014). The gene discussed is ALK; the disease is non-small cell lung carcinoma.